Benlysta Belimumab

Benlysta (belimumab) is a B-lymphocyte stimulator (BLyS)-specific inhibitor used for the treatment of:

• patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy; 
• adults with active lupus nephritis (LN) who are receiving standard therapy.

Limitations of Use: The efficacy of this therapeutic drug has not been evaluated in patients with severe active central nervous system lupus. This drug has not been assessed along with other biologics. The use of Benlysta is not recommended in these scenarios. 

Recommended Dosage: Benlysta may be administered as an intravenous (IV) infusion in patients aged 5 years and older or as a subcutaneous (SC) injection in patients aged 18 years and older. Benlysta vials are intended for IV use only (not for SC use) and autoinjectors and prefilled syringes are intended for SC use only (not for IV use). 

Intravenous Administration in Adults with SLE or Lupus Nephritis and Pediatric Patients with SLE: The recommended IV dosage regimen is 10 mg/kg at 2-week intervals for the initial 3 doses and at 4-week intervals thereafter. Reconstitute, dilute and administer as an IV infusion over a period of 60 minutes. The rate of infusion may be slowed or interrupted in case of an infusion reaction. The infusion must be stopped promptly if the patient experiences a critical hypersensitivity reaction.

Subcutaneous (SC) Administration in Adults with SLE: The recommended dosage is 200 mg once weekly given as an SC injection in the abdomen or thigh. SC dosing is not based on weight. If transitioning from IV therapy with Benlysta to SC administration, administer the first SC dose 1-4 weeks after the last IV dose.

Subcutaneous (SC) Administration in Adults with Lupus Nephritis: The recommended dosage regimen is a 400 mg dose (two 200-mg injections) once weekly for 4 doses, then 200 mg once weekly thereafter. The dose is given via SC injection in the abdomen or thigh. A patient with lupus nephritis may transition from IV therapy with Benlysta to SC therapy any time after the patient completes the first 2 IV doses. In case of transitioning, administer the first SC dose of 200 mg 1-2 weeks after the final intravenous (IV) dose.

• Serious and occasionally fatal infections may develop in patients receiving immunosuppressive agents, including Belimumab. Consider the risks and benefits before starting treatment in those with serious or chronic infections. Consider interrupting therapy in patients who develop a new infection while receiving it and monitor these patients precisely.
• Acute hypersensitivity reactions, including anaphylaxis and death, have been noticed in association with Belimumab. Monitor patients throughout the infusion and for an appropriate time after intravenous (IV) administration of Belimumab injection. Consider administering premedication as prophylaxis before intravenous (IV) dosing.
• Evaluate the risk of depression and suicide considering the patient’s medical history and current psychiatric status before this therapy and continue to monitor patients during therapy. Instruct patients receiving this medication (and caregivers, if applicable) to contact their clinician in case they experience any new or worsening depression, suicidal thoughts or behavior, or other mood changes.
• Treatment with Belimumab has not been evaluated together with other biological therapies, including B-cell targeted therapies. Therefore, the use of this therapeutic drug is not recommended in conjunction with biological therapies.

What documents are required to import BENLYSTA to India?

BENLYSTA (belimumab) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

BENLYSTA (belimumab injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Benlysta in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of BENLYSTA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Benlysta injection price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the BENLYSTA (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Benlysta®?

Belimumab is a Generic Name for the trade name drug Benlysta®.

What is the Manufacturer’s Name of Benlysta®?

Benlysta® is manufactured by Human Genome Sciences, Inc.

Is Benlysta® approved by the FDA?

Yes, Benlysta® is approved by the FDA. Date of first approval: March 10, 2011.

What is the dosage and form of Benlysta® supplied?

Benlysta® is supplied as injections of 120 mg or 400 mg/vial (for intravenous use) and 200 mg/mL (for subcutaneous use. 

What are the most common side effects of Benlysta®? 

The most common side effects of Benlysta® are diarrhea, migraine, depression, pyrexia, nasopharyngitis, bronchitis, pain in extremity, insomnia, pharyngitis, nausea, and injection site reactions (subcutaneous administration).

How much does Benlysta® cost in India?

The cost of Benlysta in India can vary. To procure it legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Benlysta®?

Store autoinjectors and prefilled syringes in the refrigerator at 36 to 46°F (2 to 8°C). Do not freeze. Keep the autoinjectors and prefilled syringes in the original package until the time of use to protect them from light. Do not shake. Keep away from heat and sunlight.

Is it safe to buy Benlysta® online in India?

Yes, one can buy Benlysta online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Benlysta® through legal channels.